A5100457768- Lung Cancer Treatments and Mutations
- Dermatology and Skin Diseases
- HER2/EGFR in Cancer Research
- Urticaria and Related Conditions
- Oral microbiology and periodontitis research
- Colorectal Cancer Treatments and Studies
- Food Allergy and Anaphylaxis Research
- Quinazolinone synthesis and applications
- Oral and gingival health research
- Signaling Pathways in Disease
- Protein Degradation and Inhibitors
- PI3K/AKT/mTOR signaling in cancer
- Ion channel regulation and function
- Asthma and respiratory diseases
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Ion Channels and Receptors
- Cancer, Lipids, and Metabolism
- Berberine and alkaloids research
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
- Cancer therapeutics and mechanisms
- Wnt/β-catenin signaling in development and cancer
- Allergic Rhinitis and Sensitization
- Bone and Dental Protein Studies
East China University of Science and Technology
2022-2025
Regeneron (United States)
2017-2025
Putian University
2025
Southern Medical University
2024
Emory University
2020-2024
Winship Cancer Institute
2020-2024
Union Hospital
2024
Chongqing Medical University
2024
Wuhan University
2024
Renmin Hospital of Wuhan University
2024
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).To assess the efficacy and safety different regimens in maintaining response after 16 initial treatment.The Study Confirm Efficacy Safety Different Dupilumab Dose Regimens Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE) was a randomized, double-blind, phase 3 clinical trial conducted from March 25, 2015, October 18, 2016, at 185 sites North America, Europe, Asia,...
Significance A critical challenge for chemotherapy is development of chemoresistance, but underlying molecular mechanisms remain unclear. In this study, we found that drug-resistant adriamycin-resistant human breast cancer cells possessed numerous transient receptor potential channel 5 (TrpC5) -containing extracellular vesicles (EVs) on the cell surface. Suppressing TrpC5 expression diminished formation EVs. Incubation drug-sensitive recipient with EVs endowed recipients properties. both...
Background: Cervical cancer is a major world health problem for women. Currently, research focuses on improving therapy cervical using various treatment options such as co-delivery of chemotherapeutic agents by nanocarriers. Purpose: The aim this study was to develop trans-activating transcriptional activator (TAT)-modified solid lipid nanoparticles (SLNs) paclitaxel (PTX) and α-tocopherol succinate-cisplatin prodrug (TOS-CDDP) (TAT PTX/TOS-CDDP SLNs) in order achieve synergistic antitumor...
5-Fluorouracil (5-Fu) is commonly used in the chemotherapy of colorectal cancer (CRC), but resistance to 5-Fu occurs most cases, allowing progression. Suppressing ABCB1 (ATP-binding cassette, subfamily B, member 1), which a pump overproduced cells export cytotoxic drugs, an attractive strategy overcome drug resistance. In present study, transient receptor potential channel TrpC5 was found be at mRNA and protein levels together with 5-Fu-resistant human CRC HCT-8 (HCT-8/5-Fu) LoVo (LoVo/5-Fu)...
Abstract Adriamycin is a first-line chemotherapy agent against cancer, but the development of resistance has become major problem. Although autophagy considered to be an adaptive survival response in and may associated with chemoresistance, its inducer underlying molecular mechanisms remain unclear. Here, we demonstrate that adriamycin up-regulates both levels TRPC5 autophagy, increase mediated by breast cancer cells. Blockade or increased sensitivity vitro vivo . Notably, revealed positive...
Osimertinib (AZD9291 or TAGRISSO) is a promising and approved third-generation EGFR tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations the resistant T790M mutation. However, inevitable emergence of acquired resistance limits its long-term efficacy. A fuller understanding mechanism action osimertinib linkage to will enable development more efficacious therapeutic strategies. Consequently, we have...
Abstract There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and develop mechanism‐driven strategies manage their acquired resistance. Transient receptor potential melastatin‐2 (TRPM2) functions as important regulator Ca 2+ influx, but its role in mediating therapeutic efficacies EGFR‐TKIs resistance has been rarely studied. This study demonstrated a previously undiscovered suppression TRPM2...
Abstract Programmed death ligand 1 (PD-L1) immune checkpoint inhibitors are promising therapeutic agents for treating cancers but the response rate is <20%. Some chemotherapeutic drugs could also activate an anticancer to kill cancer cells, apart from their direct cytotoxicity. Our study investigated combination of with PD-L1 antibody enhance blockade. Non-small cell lung (NSCLC) cells were pre-treated mitomycin C (MMC) and then co-cultured peripheral blood mononuclear (PBMCs) investigate...
Commercial xylose purification produces mother liquor (XML) as a major byproduct, which has become an inexpensive and abundant carbon source. A portion of this XML been used to produce low-value-added products such caramel but the remainder often ends up organic pollutant. This issue industrial concern. In study, uracil-deficient Candida tropicalis strain was engineered efficiently convert commercially useful product xylitol.The xylitol dehydrogenase gene deleted block conversion xylulose....
Development of effective strategies to manage the inevitable acquired resistance osimertinib, an approved 3rd generation EGFR inhibitor for treatment mutant (EGFRm) non-small cell lung cancer (NSCLC), is urgently needed. This study reported that DNA topoisomerase II (Topo II) inhibitors, doxorubicin and etoposide (VP-16) synergistically decreased survival with enhanced induction damage apoptosis in osimertinib-resistant cells, suppressed growth tumors, delayed emergence osimertinib...
Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune diseases. However, the effectiveness of BTK inhibitors limited by side effects drug resistance. In this study, we report development novel proteolysis targeting chimeras (PROTACs) with different classes BTK-targeting ligands (e.g., spebrutinib) other than ibrutinib. Compound 23 was identified as a potent fast PROTAC degrader, exhibiting outstanding degradation potency efficiency Mino cells (DC50, 4 h = 1.29...
Abstract Cephalosporin C (CPC) is a critical raw material for cephalosporin antibiotics produced by Acremonium chrysogenum . During fermentation, the oxygen supply crucial factor limiting efficient biosynthesis of CPC. This study demonstrated that addition exogenous surfactants significantly increased dissolved (DO) level, extracellular catalase content, and final CPC titer. Consequently, we hypothesized examined correlation between in A. through both hydrogen peroxide (H₂O₂) endogenous...
Neoadjuvant chemoimmunotherapy (nICT) has emerged as a novel and promising treatment model for esophageal squamous cell carcinoma (ESCC). However, the optimal interval to esophagectomy after nICT remains unclear. This study aimed explore impact of prolonged (7-10 weeks) on short- long-term outcomes compared standard (4-6 weeks). was multicenter retrospective cohort analysis, including three centers. Patients were diagnosed with locally advanced ESCC (cT3-4a or cN+) received radical resection...
In cancer cells, intracellular Ca2+ homeostasis is altered, and this involved in tumor initiation, progression, metastasis. However, little known about the underlying mechanisms. Here, we report that transient receptor potential channel 5 (TrpC5), a receptor-activated non-selective channel, correlated with metastasis colon patients. Moreover, overexpression of TrpC5 caused robust rise concentration ([Ca2+]i), decreased E-cadherin, increased mesenchymal biomarker expression, then promoted...
Abstract Expression of programmed death-ligand 1 (PD-L1) on cancer cells is a critical mechanism contributing to immunosuppression and immune escape. PD-L1 expression may also affect therapeutic outcomes epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR-mutant non–small cell lung cancers (NSCLC) can even be altered during the treatment albeit largely undefined mechanisms. This study primarily focuses elucidating by which osimertinib...
The currently available antihypertensive agents have undesirable adverse effects due to systemically altering target activity including receptors, channels, and enzymes. These effects, such as loss of potassium ions induced by diuretics, bronchospasm beta-blockers, constipation Ca2+ channel blockers, dry cough ACEI, lead non-compliance with therapies (Moser, 1990). Here, based on new hypertension mechanisms, we explored a approach. We report that transient receptor potential vanilloid 4...
Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit-risk profile. However, non-steroidal immunosuppressants (NSISS) are often used therapy clinical practice. Impact of prior NSISS on dupilumab's effect vs. control has not been described previously. This study assessed efficacy patients AD, comparing with/without therapy, four phase 3 trials.This post hoc analysis...
The inevitable acquired resistance to osimertinib (AZD9291), an FDA-approved third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring activating or T790M resistant mutations, limits its long-term clinical benefit. Telomere maintenance via telomerase reactivation is linked uncontrolled growth and a hallmark attractive therapeutic target. Our effort toward understanding action mechanisms, including has...